A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain.

Alshehre, SM and Duffy, S and Jones, G and Ledger, WL and Metwally, M (2020) A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain. Reprod Biol Endocrinol, 18. ISSN 1477-7827 DOI: https://doi.org/10.1186/s12958-020-00586-z

Abstract

Download

[img]
Preview

Export Citation

Share

Statistics

Additional statistics for this record